Document is current
Any future updates will be listed below
-
Authors
Wong, Derek
Tageldein, Maha https://orcid.org/0000-0002-0165-0828
Luo, Ping https://orcid.org/0000-0002-0039-747X
Ensminger, Erik https://orcid.org/0000-0001-5237-5179
Bruce, Jeffrey
Oldfield, Leslie
Gong, Haifan
Fischer, Nicholas William https://orcid.org/0000-0003-4672-0532
Laverty, Brianne
Subasri, Vallijah https://orcid.org/0000-0002-6584-877X
Davidson, Scott
Khan, Reem
Villani, Anita
Shlien, Adam https://orcid.org/0000-0002-0368-5370
Kim, Raymond H. https://orcid.org/0000-0002-2147-8674
Malkin, David https://orcid.org/0000-0001-5752-9763
Pugh, Trevor J. https://orcid.org/0000-0002-8073-5888
- License Information
-
More Information
Article History
Received: 11 September 2023
Accepted: 7 August 2024
First Online: 27 August 2024
Competing interests
: DW reports funding support from the Princess Margaret Cancer Foundation, the Canadian Institutes for Health Research, and the Children’s Tumor Foundation. EE reports funding support from the Canadian Cancer Society. RHK reports grants from the Princess Margaret Cancer Foundation, the Canadian Institutes for Health Research, TD Ready Challenge, and McLaughlin Centre for Molecular Medicine. DAM reports consultancy/advisory board for ymAbs Therapeutics, EUSA Pharma and Clarity Pharmaceuticals (compensated). TJP reports grants from Terry Fox Research Institute, Canadian Institutes for Health Research, TD Ready Challenge, and MacLaughlin Centre at the University of Toronto during the conduct of the study; consultation for Illumina, AstraZeneca, Merck, Chrysalis Biomedical Advisors, SAGA Diagnostics, and the Canadian Pension Plan Investment Board (compensated); and receives research support (institutional) from Roche/Genentech. No disclosures were reported by the other authors.
